2025 Global Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 Global Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global antisense and RNAi therapeutics market are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Biogen Inc., and Sarepta Therapeutics. Alnylam Pharmaceuticals leads with a robust pipeline in RNAi therapies targeting diverse tissues worldwide and strategic partnerships, including a major collaboration with Roche to co-develop and commercialize treatments like zilebesiran. Ionis Pharmaceuticals is notable for its antisense technology product approvals, such as Wainua for hereditary amyloidosis, and partnerships with companies like AstraZeneca to develop novel antisense drugs.
Biogen focuses on neurodegenerative diseases using antisense and RNAi therapeutics, capitalizing on the large patient populations in this segment, essential for market growth. Sarepta Therapeutics heavily invests in RNA-based medicines for genetic disorders, enhancing its global footprint with innovative nucleic acid therapies and expanding clinical pipelines. These companies drive the market’s growth by advancing gene-silencing technologies, pushing regulatory approvals, and forming global collaborations that accelerate the development and delivery of treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global antisense and RNAi therapeutics market are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Biogen Inc., and Sarepta Therapeutics. Alnylam Pharmaceuticals leads with a robust pipeline in RNAi therapies targeting diverse tissues worldwide and strategic partnerships, including a major collaboration with Roche to co-develop and commercialize treatments like zilebesiran. Ionis Pharmaceuticals is notable for its antisense technology product approvals, such as Wainua for hereditary amyloidosis, and partnerships with companies like AstraZeneca to develop novel antisense drugs.
Biogen focuses on neurodegenerative diseases using antisense and RNAi therapeutics, capitalizing on the large patient populations in this segment, essential for market growth. Sarepta Therapeutics heavily invests in RNA-based medicines for genetic disorders, enhancing its global footprint with innovative nucleic acid therapies and expanding clinical pipelines. These companies drive the market’s growth by advancing gene-silencing technologies, pushing regulatory approvals, and forming global collaborations that accelerate the development and delivery of treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
